Syncona gains as Beacon gene therapy trial meets endpoint
Shares of British healthcare investment firm Syncona rose 6% to 118 pence after its portfolio company Beacon Therapeutics' Phase II/III VISTA trial met the FDA-endorsed primary endpoint for gene therapy laru-zova. The response rate was 31% in the high-dose arm and 24.1% in the low-dose arm, supporting plans for regulatory discussions and a rolling US biologics licence application submission later in 2026. The stock is up approximately 24% year-to-date.
Shares of British healthcare investment firm Syncona were up 6% at 118 pence after the company said portfolio company Beacon Therapeutics’ Phase II/III VISTA trial met the FDA-endorsed primary endpoint for gene therapy laru-zova. 1% in the low-dose arm. Syncona said the data supports Beacon’s plans to begin regulatory discussions and start a rolling US biologics licence application submission later in 2026. The stock is up about 24% year to date.